Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents
- 31 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 70 (6), 1691-1704
- https://doi.org/10.1007/s00262-020-02793-4
Abstract
Background Anti-PD-(L)1 blocking agents can induce immune-related adverse events (irAEs), which can compromise treatment continuation. Since circulating leukocyte-platelet (PLT) complexes contribute to inflammatory and autoimmune diseases, we aimed to analyze the role of these complexes as predictors of irAEs in non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1. Materials and methods Twenty-six healthy donors (HD) and 87 consecutive advanced NSCLC patients treated with anti-PD-(L)1 were prospectively included. Percentages of circulating leukocyte-PLT complexes were analyzed by flow cytometry and compared between HD and NSCLC patients. The association of leukocyte-PLT complexes with the presence and severity of irAEs was analyzed. Results NSCLC patients had higher percentages of circulating leukocyte-PLT complexes. Higher percentages of monocytes with bound PLT (CD14 + PLT +) were observed in patients who received prior therapies while CD4 + T lymphocytes with bound PLT (CD4 + PLT +) correlated with platelets counts. The CD4 + PLT + high percentage group presented a higher rate of dermatological irAEs while the CD4 + PLT + low percentage group showed a higher rate of non-dermatological irAEs (p < 0.001). A lower frequency of grade >= 2 irAEs was observed in the CD4 + PLT + high percentage group (p < 0.05). Patients with CD4 + PLT + low and CD14 + PLT + high percentages presented a higher rate of grade >= 3 irAEs and predominantly developed non-dermatological irAEs (p < 0.01). Conclusions Our results suggest that circulating leukocyte-PLT complexes and the combination of CD4 + PLT + and CD14 + PLT + percentages can be used as a predictive biomarker of the development and severity of irAEs in advanced NSCLC patients receiving anti-PD-(L)1 agents.Funding Information
- Bristol-Myers Squibb
This publication has 46 references indexed in Scilit:
- Functional consequences of platelet binding to T lymphocytes in inflammationJournal of Leukocyte Biology, 2013
- Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes MetastasisCancer Cell, 2011
- Modulation of Natural Killer Cell Anti-Tumor Reactivity by PlateletsJournal of Innate Immunity, 2011
- Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their ManagementSeminars in Oncology, 2010
- Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseasesJournal of Leukocyte Biology, 2008
- Platelet–lymphocyte cross-talkJournal of Leukocyte Biology, 2008
- Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish populationMutation research. Reviews in mutation research, 2006
- Platelet–lymphocyte conjugation differs between lymphocyte subpopulationsJournal of Thrombosis and Haemostasis, 2006
- Differential Expression of α3 Fucosyltransferases in Th1 and Th2 Cells Correlates with Their Ability to Bind P-SelectinBiochemical and Biophysical Research Communications, 1998
- Activated platelets signal chemokine synthesis by human monocytes.JCI Insight, 1996